Dexcom and Beyond Type 1 survey on CGM: awareness, cost, mental effort still major issues in T1D

Dexcom and Beyond Type 1 commissioned a nationwide survey of people with type 1 diabetes (n=1,002) to assess adoption and awareness of diabetes technology, including CGM. Download the full PDF file here.

Adults with type 1 diabetes over the age of 18 were surveyed between September and October 2018 in a panel sourced from Lucid (a market research firm that does not specialize in diabetes). The survey population was predominantly female (75%) and white (83%); the response rate and compensation were not given.

See below for our top takeaways from the results. There’s clearly a tremendous amount of work that needs to be done in terms of raising awareness of CGM – both within people with type 1 and their healthcare providers! Dexcom/BT1 also have a one-page website up:

Awareness of Diabetes Technology

  • 8% of respondents indicated that they had “never” heard of CGM, while another 27% said they “know a little about it, but have never used it.” That leaves one-third of the market where awareness/education could drive more uptake alone! Only 27% said they currently use CGM – depending on how representative this sample is (completely unclear), that could over- or under-represent CGM penetration in type 1 diabetes. Interestingly, the numbers looked pretty similar for Bluetooth-enabled BGMs.

  • 54% of respondents were not aware that there CGMs that eliminated the need for fingersticks. Clearly there is a lot of potential for both Abbott’s FreeStyle Libre and Dexcom’s G6 to market no-fingerstick sensors! A notable 80% of respondents also indicated that they still prick their finger at least three times daily.
  • Awareness of specific CGM options on the market was fairly even between Abbott, Dexcom, and Medtronic. Given that Senseonics’ Eversense just launched in the US in July, we’re not surprised that the vast majority of participants (74%) indicated never having heard of the device. It was interesting to see that a greater proportion of participants reported knowing a “little” about Abbott’s FreeStyle Libre but had never used one as compared to Dexcom (41% vs. 26%). This is not surprising either, as FreeStyle Libre only launched in the US last fall. The greatest proportion of patients (16%) reported using Dexcom currently, with Medtronic’s Guardian Connect surprisingly not far behind at 10%. We’d note that answers to “I currently use one” don’t quite line up with the above – the below suggests 31% CGM usage in the survey, while the above suggests 27%. Are some users utilizing multiple devices?

  • Over 30% of respondents reported that their doctor who manages their diabetes “seldom” or “never” brings up new diabetes management technology. Given that 68% of participants indicated that they received information regarding the CGM they currently use from their healthcare provider, it’s clearly very important that providers are recommending and remaining aware of new diabetes technology. Lots of work to do here too!

Patient Access and Attitudes Surrounding CGM

  • The most commonly cited reason for why participants are not using CGM is lack of insurance coverage (34%!), followed by their providers not prescribing CGM (25%). Yikes, especially considering these are people with type 1 diabetes that were willing to take an online survey! Another 11% said they don’t know enough, another clear opportunity. Reimbursement for CGM is often highlighted as “done” in type 1 diabetes, but that is clearly not in the case in this survey. Medicaid coverage of CGM also varies by state, and out-of-pocket costs can also be high even if insurance does cover it.
  • CGM users reported being significantly more satisfied with their health-related quality of life than non-CGM users (53% vs. 34%), and 96% of CGM users would recommend CGM to other patients. Still, nearly 80% of users didn’t start CGM until more than three years following diagnosis – no surprise, considering this was a survey of adults (18+ years).
  • When asked to indicate the top three benefits of CGM that they find most appealing, the most commonly cited features were: (i) alerts and alarms (74%); (ii) continuous glucose readings sent automatically to receiver or smartphone (59%); and (iii) no fingerpricks for calibration or treatment decisions (50%). It’s interesting that insulin automation prompted by CGM was not even listed!

Patient Perspectives on Diabetes Burden

  • Notably, 41% of participants reported being hospitalized for health issues related to type 1 diabetes >1 time(s) in the last 18 months – over 400 people. That sounds very high – unreasonably high. A full 13% or 130 people had been hospitalized >3 times. Yikes – that also sounds far too high. This could be a reality check on living with type 1 diabetes, which remains so dangerous or it could be that this sample is not representative. If it is representative, that would bean that 615,000 people with type 1 in the US were hospitalized over the last 18 months – that sounds too high – and that nearly 200,000 people with type 1 were hospitalized more than three times over the 18 months – this sounds possible but also very high. We wonder if there would be meaningful differences in hospitalization frequency for CGM vs. SMBG users or pump vs. MDI users.

  • Type 1 diabetes continues to takes up valuable headspace – 64% of participants agreed or strongly agreed that they frequently worry about hypoglycemia, and 69% agreed or strongly agreed that they frequently worry about hyperglycemia. An even larger proportion of participants (81%) agreed or strongly agreed that they frequently worry about long-term diabetes-related complications – another worry on top of the daily highs and lows. When asked to choose the top three burdens or issues associated with diabetes, participants most commonly selected fear of long-term complications (74%), fear of passing out/having a serious “low” event (54%), and multiple injections every day (38%).


Great find @Mila :+1:t3:

1 Like